Q-Line Biotech Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dwrk69uag4r2s9qf9uliydwm.pdf

Key Takeaways


The Manufacturing-Led Margin Inflection

Ajay Mahanty: "Every new instrument installed creates a long-term opportunity for recurring reagent sale. This creates a razor-blade business model that help build visibility and sustainability in revenue."

Installed Base & The Razor-Blade Model

Ajay Mahanty: "Our main business objective is to get the more reagent business actually, not to put more number of not to sell hardware more, but of course both are you can say part and parcel. Without analyzer we cannot drive the reagent business."

FY27 Growth Roadmap

Ajay Mahanty: "In next 2 to 3 years definitely the quantity we are producing here at Delhi, I think it is not 3x, it will be at least 6x to 7x."

CDMO: The Emerging Export Optionality

Y.S. Prabhakara: "Margins will grow up by about 10 percentage points or so... about 10% to 15% we retain as gross margin in the domestic for the instruments, whereas that could be easily 25% plus we see depending upon how our negotiations we are able to master."

Product Pipeline & Market Positioning

Saurabh Garg: "So, now we are very much focused and driving very focussedly to the market. We are not distracting jumping and hunky monkey jumping. So, we'll focus and we will do this type of way."

Balance Sheet, Governance & Concentration


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth30-35% topline growthFY27
Reagent revenue growth35% increase, driven by installed baseFY27
Instrument placements2,000+ new installations including overseas; 300-400 specifically plannedFY27
Export growthMore than 5x (excluding CDMO)FY27
CDMO revenue~INR10 crores, traction in Q3/Q4FY27
Unit 4 capacity utilization25-30% of capacityEnd-FY27
EBITDA marginsSlightly better than FY26FY27
Working capital days~100 daysFY27
Receivable cycleWithin 90-120 daysFY27
B2G vs trade mix50-50End-FY28
Unit 4 revenue scale3-4x of current revenueBy FY30
Delhi production scale6-7x current quantityNext 2-3 years
CapexNo major capex expectedNext 2 years
Corporate guaranteesNo new guarantees; existing ones wound down to minimalOngoing (no timeline given)

Key Metrics

MetricFY26
Revenue from operations₹341.7 cr, +9% YoY
Gross margin60.8%, +750 bps YoY
EBITDA₹98.1 cr, +39% YoY
EBITDA margin28.7%, +620 bps YoY
PAT₹55.7 cr, vs ₹19.2 cr in FY25
PAT margin16.3%, vs 6.1% in FY25
Net worth~₹246 cr at end of FY26
FY27 revenue growth guidance30% to 35%
Reagent revenue share~70% of total revenue
Reagent revenue growth35% in FY26
Manufactured reagent sales growth~70% in FY26
In-house manufacturing share (reagents)70% manufactured, 30% traded
Selectra Pro M cumulative installed base>1,550 instruments
Total instruments added in last 2 years2,500 (1,550 Selectra Pro M + 1,053 hematology analyzers)
Total cumulative instrument base16,000–17,000 instruments
FY27 planned instrument additions~2,000 instruments
Export revenue~₹1.2 cr in FY26
FY27 export growth target>5x (excluding CDMO)
FY27 CDMO revenue target~₹10 cr
Revenue concentration (UP)77% of revenue
B2G vs trade revenue mix65% B2G, 35% trade
R&D spend~₹5 cr in FY26
Receivable days134 days in FY26